Printer Friendly

NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE

 BOULDER, Colo., Aug. 24 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) today announced that the first patient has been enrolled in its ANTRIL(TM) follow-up severe sepsis clinical trial.
 This randomized, double-blind, placebo-controlled trial is being conducted in 11 countries in North America and Europe and involves approximately 75 medical centers. The primary objective of this study is to provide further evidence of the efficacy and safety of ANTRIL (interleukin-1 receptor antagonist or IL-1ra) compared to placebo in increasing survival time in patients with presumed severe sepsis and a 28-day predicted risk of mortality of greater than or equal to 24 percent at study entry.
 Patient enrollment will continue until about 900 evaluable patients with a predicted risk of mortality of greater than or equal to 24 percent have received ANTRIL or placebo. To reach 900 evaluable patients, the company anticipates that approximately 1,400 total patients must be enrolled.
 "I am extremely proud of all the people involved in making it possible to start this important trial on schedule, five months after the results from Synergen's previous sepsis study were presented in Brussels, Belgium," said Larry Soll, Ph.D., chairman and chief executive officer of Synergen.
 In a Phase III sepsis study completed in late 1992, a retrospective analysis of survival of high risk patients (who had a predicted risk of mortality of greater than or equal to 24 percent) indicated that these more severely ill patients benefited most from ANTRIL (22 percent reduction in mortality compared to placebo). Because this was not prospectively defined, Synergen decided to conduct a follow-up trial focusing on patients with severe sepsis.
 "With the valuable data compiled from the previous study and a diagnostic method that can be used prospectively to predict which patients may benefit from ANTRIL, we are hopeful that this new clinical trial will result in the data necessary to apply for a license application with the FDA," said Dr. Soll.
 Sepsis is the clinical complex of signs and symptoms that result from severe systemic response to infection. Interleukin (IL-1) has been shown to be a major mediator of the inflammatory response to sepsis. Because ANTRIL blocks the action of IL-1, it is being tested as a new therapy for sepsis and other inflammatory disorders.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted toward products for inflammatory disorders and neurological diseases. The company is headquartered in Boulder, with manufacturing operations in Boulder and Delaware and operations in The Netherlands and Japan.
 -0- 8/24/93
 /CONTACT: Paul Laland (Media), 303-541-1325; or Debra Bannister (Financial), 303-938-6242, both of Synergen/
 (SYGN)


CO: Synergen Inc. ST: Colorado IN: MTC SU:

MC -- DV001 -- 5420 08/24/93 11:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1993
Words:456
Previous Article:FORD MOTOR COMPANY REPORTS U.S. SALES
Next Article:PENTAGON NAVAL ADVISOR AND NOTED DEFENSE INDUSTRY EXECUTIVE JOIN MERCHANT BANKING FIRM
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters